One of the most interesting trends in AI for drug discovery isn't molecule generation.
It's molecule recovery. 🧬
The AMREC framework highlights a subtle but important shift.
github.com/aipoch/medical-re…
When an LLM generates an invalid molecule, the goal is no longer simply to "fix the syntax."
The goal is to preserve scientific intent.
AMREC approaches this through a multi-agent workflow involving:
• Checking
• Critique
• Planning
• Candidate exploration
Combined with chemistry-aware validation tools.
In other words, the system doesn't just ask:
"Can this molecule be repaired?"
It asks:
"Can this molecule be repaired while preserving the biological idea behind it?"
That's a much harder problem.
And it reflects a broader trend we're seeing across AI-driven science:
Generation → Reflection → Recovery → Validation
As scientific agents become more capable, success will increasingly depend on how well they handle mistakes, not just how often they avoid them.
At AIPOCH, we think the same principle applies across biomedical research workflows.
Whether it's literature synthesis, biomarker discovery, protocol design, or translational research, the challenge isn't generating more outputs.
It's ensuring those outputs can survive evidence review, scientific scrutiny, and iterative refinement.
Because in science, the most valuable workflow isn't the one that never makes mistakes.
It's the one that can reliably detect and recover from them. 🔬